Efficacy and Safety of 5% Minoxidil Foam in Female Androgenetic Alopecia

Inclusion Criteria: * Voluntarily participate in the study and be able to provide a written Informed Consent Form (ICF); * Female aged ≥ 18 years; * Investigator-diagnosed androgenetic alopecia; * Hair loss severity graded D3 to D6 on the Savin scale; * Willingness to maintain identical hairstyle, hair color, and hair length at each follow-up visit; * No pregnancy plans during the study and for 3 months post-last dose, with commitment to highly effective contraception. Women of childbearing potential must have negative serum pregnancy test ≤7 days prior to first investigational product administration Exclusion Criteria: * Trial participants with known hypersensitivity to minoxidil or any excipient of the investigational product. * Trial participants with known hair loss disorders other than androgenetic alopecia (AGA) * Trial participants with any scalp disorder at screening that may interfere with efficacy evaluation, as determined by the investigator. * Lactating women * Trial participants with history of hypotension or uncontrolled hypertension * Trial participants with clinically significant abnormal laboratory findings at screening that may compromise efficacy and safety assessments, as determined by the investigator. * Trial participants with clinically significant ECG abnormalities at screening * Trial participants with history of malignancy prior to screening. * Trial participants known to have conditions or disorders that may affect hair growth or compromise study…